Use Of 5α-Reductase Inhibitors And Survival Of Esophageal And Gastric Cancer In A Nationwide Swedish Cohort Study

    May 2023 in “ Acta Oncologica ”
    Sirus Rabbani, Fredrik Mattsson, Jesper Lagergren, Shao‐Hua Xie
    Studysummary This Swedish cohort study found no association between the use of anti-androgenic 5α-reductase inhibitors and improved 5-year all-cause or disease-specific mortality in oesophago-gastric cancer patients, challenging the hypothesis that these drugs enhance survival outcomes.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on tandfonline.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Anti-Androgen Hormonal Therapy for Cancer and Other Diseases European Journal of Pharmacology · 2019
    2. An Observational Retrospective Evaluation of 79 Young Men with Long-Term Adverse Effects After Use of Finasteride Against Androgenetic Alopecia International Journal of Andrology · 2016
    3. An Overview on 5α-Reductase Inhibitors Steroids · 2009
    4. 5α-Reductase Activity in the Prostate Urology · 2001